当前位置: 首页 > 期刊 > 《中国药房》 > 20193
编号:13565294
分化型甲状腺癌患者术后左甲状腺素最佳初始剂量预测模型探讨(5)
http://www.100md.com 2019年2月1日 《中国药房》 20193
     [18] OJOMO KA,SCHNEIDER DF,REIHER AE,et al. Using body mass index to predict optimal thyroid dosing after thyroidectomy[J]. J Am Coll Surg,2013,216(3):454- 460.

    [19] MISTRY D,ATKIN S,ATKINSON H,et al. Predicting thyroxine requirements following total thyroidectomy[J]. Clinical Endocrinology,2011,74(3):384-387.

    [20] WANG LY,SMITH AW,PALMER FL,et al. Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma[J]. Thyroid,2015,25(3):300-307.

    [21] SEVERI S,MALAVOLTI M,BATTISTINI N,et al. Some applications of indirect calorimetry to sports medicine[J]. Acta Diabetologica,2001,38(1):23-26.

    [22] MOREIRA DG,MARASSI MP,CORREA DA COSTA VM,et al. Effects of ageing and pharmacological hypothyroidism on pituitary-thyroid axis of dutch-miranda and wistar rats[J]. Experimental Gerontology,2005,40(4):330- 334.

    [23] ABONOWARA A,QURAISHI A,SAPP JL,et al. Prevalence of atrial fibrillation in patients taking TSH suppression therapy for management of thyroid cancer[J]. Clin Invest Med,2012,35(3):E152-E156.

    [24] 李二樂,拓明祥,田青.良性甲状腺结节切除术后口服左旋甲状腺素片效果的随访研究[J].延安大学学报(医学科学版),2018,16(2):35-38.

    (收稿日期:2018-09-21 修回日期:2018-12-18)

    (编辑:邹丽娟), 百拇医药(李林通 计成 严思敏 桑剑锋 葛卫红)
上一页1 2 3 4 5